Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report

The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokumaru, Yoshihisa, Matsuhashi, Nobuhisa, Takahashi, Takao, Tanahashi, Toshiyuki, Matsui, Satoshi, Imai, Hisashi, Tanaka, Yoshihiro, Yamaguchi, Kazuya, Yoshida, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482389/
https://www.ncbi.nlm.nih.gov/pubmed/31031973
http://dx.doi.org/10.3892/mco.2019.1836
_version_ 1783413878265217024
author Tokumaru, Yoshihisa
Matsuhashi, Nobuhisa
Takahashi, Takao
Tanahashi, Toshiyuki
Matsui, Satoshi
Imai, Hisashi
Tanaka, Yoshihiro
Yamaguchi, Kazuya
Yoshida, Kazuhiro
author_facet Tokumaru, Yoshihisa
Matsuhashi, Nobuhisa
Takahashi, Takao
Tanahashi, Toshiyuki
Matsui, Satoshi
Imai, Hisashi
Tanaka, Yoshihiro
Yamaguchi, Kazuya
Yoshida, Kazuhiro
author_sort Tokumaru, Yoshihisa
collection PubMed
description The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL and CTX treatment.
format Online
Article
Text
id pubmed-6482389
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-64823892019-04-26 Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report Tokumaru, Yoshihisa Matsuhashi, Nobuhisa Takahashi, Takao Tanahashi, Toshiyuki Matsui, Satoshi Imai, Hisashi Tanaka, Yoshihiro Yamaguchi, Kazuya Yoshida, Kazuhiro Mol Clin Oncol Articles The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL and CTX treatment. D.A. Spandidos 2019-06 2019-04-03 /pmc/articles/PMC6482389/ /pubmed/31031973 http://dx.doi.org/10.3892/mco.2019.1836 Text en Copyright: © Tokumaru et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Tokumaru, Yoshihisa
Matsuhashi, Nobuhisa
Takahashi, Takao
Tanahashi, Toshiyuki
Matsui, Satoshi
Imai, Hisashi
Tanaka, Yoshihiro
Yamaguchi, Kazuya
Yoshida, Kazuhiro
Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
title Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
title_full Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
title_fullStr Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
title_full_unstemmed Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
title_short Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
title_sort efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482389/
https://www.ncbi.nlm.nih.gov/pubmed/31031973
http://dx.doi.org/10.3892/mco.2019.1836
work_keys_str_mv AT tokumaruyoshihisa efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT matsuhashinobuhisa efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT takahashitakao efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT tanahashitoshiyuki efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT matsuisatoshi efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT imaihisashi efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT tanakayoshihiro efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT yamaguchikazuya efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport
AT yoshidakazuhiro efficacyofcombinationtherapywithzoledronicacidandcetuximabforunresectablerectalcancerwithbonemetastasesacasereport

Ejemplares similares